Vevorisertib

Name: Vevorisertib
Brand: TargetMol
SKU: T38847
Rating: 4.5 (1 reviews)

还可以

产品编号 T38847Cas号 1416775-46-6

别名 Vevorisertib, ARQ 751

Vevorisertib (ARQ 751) is a highly effective oral compound that selectively inhibits pan-AKT serine/threonine kinases such as AKT1 (with an IC50 value of 0.55 nM), AKT2 (with an IC50 value of 0.81 nM), and AKT3 (with an IC50 value of 1.31 nM). This compound, either as a standalone treatment option or in combination with other anti-cancer agents, is ideally suited for conducting research on solid tumors characterized by PIK3CA/AKT/PTEN mutations[4].

Vevorisertib

还可以

产品编号 T38847 别名 Vevorisertib, ARQ 751Cas号 1416775-46-6

规格	价格	库存	数量
25 mg	¥ 10,600	1-2周

大包装 & 定制

加入购物车

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

实验操作小课堂

常见问题解答

联系我们获取更多批次信息

资源下载

产品操作手册

产品介绍

生物活性

产品描述	Vevorisertib (ARQ 751) is a highly effective oral compound that selectively inhibits pan-AKT serine/threonine kinases such as AKT1 (with an IC50 value of 0.55 nM), AKT2 (with an IC50 value of 0.81 nM), and AKT3 (with an IC50 value of 1.31 nM). This compound, either as a standalone treatment option or in combination with other anti-cancer agents, is ideally suited for conducting research on solid tumors characterized by PIK3CA/AKT/PTEN mutations[4].
靶点活性	Akt3:1.31 nM (IC50), Akt2:0.81 nM (IC50), Akt1:0.55 nM (IC50)
体外活性	Vevorisertib binds to wild-type AKT1 and mutant AKT1-E17K with K d of 1.2 nM and 8.6 nM, respectively, and suppresses pAKT(S473) in 293T cells transiently transfected with AKT1-E17K[4].
体内活性	Vevorisertib (10~120 mg/kg) exerts dose-dependent anti-tumor activity in an AKT1-E17K mutant endometrial patient-derived xenograft (PDX) model. Vevorisertib shows a plasma half-life of 4 to 5 hours and no tissue accumulation[4].
别名	Vevorisertib, ARQ 751